Enhanced tumor cures after Foscan photodynamic therapy combined with the ceramide analog LCL29. Evidence from mouse squamous cell carcinomas for sphingolipids as biomarkers of treatment response

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 521-527

  Separovic, D ^a   Bielawski, J ^b   Pierce, J S ^b   Merchant, S ^c   Tarca, A L ^d   Bhatti, G ^a   Ogretmen, B ^b   Korbelik, M ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d Wayne State University   (United States)

Author keywords

C6 pyridinium ceramide; Ceramide; Dihydroceramide; Dihydrosphingosine; Dihydrosphingosine 1 phosphate; Foscan; Photodynamic therapy; Sphingolipids; Sphingosine 1 phosphate; Squamous cell carcinoma

Indexed keywords

C16 CERAMIDE; C18 CERAMIDE; CERAMIDE; DIHYDROCERAMIDE; LCL29; PYRIDINIUM DERIVATIVE; SPHINGANINE; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE; TEMOPORFIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG STRUCTURE; FEMALE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; CERAMIDES; DISEASE MODELS, ANIMAL; FEMALE; HEAD AND NECK NEOPLASMS; MESOPORPHYRINS; MICE; MICE, INBRED C3H; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PYRIDINIUM COMPOUNDS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPHINGOLIPIDS; TREATMENT OUTCOME;

EID: 78651240947     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.863     Document Type: Article

References (39)

1. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J and Peng Q: Photodynamic Therapy: Review. J Natl Cancer Inst 90: 889-902, 1998.
2. Castano AP, Mroz P and Hamblin MR: Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6: 535-545, 2006.
3. Wilson JJ, Jones H, Burock M, Smith D, Fraker DL, Metz J, Glatstein E and Hahn SM: Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. Int J Oncol 24: 711-717, 2004.
4. Rhodes LE, de Rie M, Enstrom Y, Groves R, Morken T, Goulden V, Wong GA, Grob JJ, Varma S and Wolf P: Photodynamic therapy using topical methyl aminolevulinate vs. surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 140: 17-23, 2004.
5. Hannun YA and Obeid LM: Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139-150, 2008.
6. Ogretmen B and Hannun YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604-616, 2004.
7. Bu S, Kapanadze B, Hsu T and Trojanowska M: Opposite effects of dihydrosphingosine 1-phosphate and sphingosine 1-phosphate on transforming growth factor-beta/Smad signaling are mediated through the PTEN/PPM1A-dependent pathway. J Biol Chem 283: 19593-19602, 2008.
8. Mielke MM and Lyketsos CG: Alterations of the sphingolipid pathway in Alzheimer's disease: New biomarkers and treatment targets? Neuromolecular Med, June 23, 2010 (Epub ahead of print).
9. Fox TE, Finnegan CM, Blumenthal R and Kester M: The clinical potential of sphingolipid-based therapeutics. Cell Mol Life Sci 63: 1017-1023, 2006.
10. Zeidan YH and Hannun YA: Translational aspects of sphingolipid metabolism. Trends Mol Med 13: 327-336, 2007.
11. Szulc ZM, Bielawski J, Gracz H, Gustilo M, Mayroo N, Hannun YA, Obeid LM and Bielawska A: Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Bioorg Med Chem 14: 7083-7104, 2006.
12. Novgorodov SA, Szulc ZM, Luberto C, Jones JA, Bielawski J, Bielawska A, Hannun YA and Obeid LM: Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J Biol Chem 280: 16096-16105, 2005.
13. Senkal CE, Ponnusamy S, Rossi MJ, Sundararaj K, Szulc Z, Bielawski J, Bielawska A, Meyer M, Cobanoglu B, Koybasi S, Sinha D, Day TA, Obeid LM, Hannun YA and Ogretmen B: Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J Pharmacol Exp Ther 317: 1188-1199, 2006.
14. Chen LB: Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4: 155-181, 1988.
15. Rossi MJ, Sundararaj K, Koybasi S, Phillips MS, Szulc ZM, Bielawska A, Day TA, Obeid LM, Hannun YA and Ogretmen B: Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells. Otolaryngol Head Neck Surg 132: 55-62, 2005.
16. Dindo D, Dahm F, Szulc Z, Bielawska A, Obeid LM, Hannun YA, Graf R and Clavien PA: Cationic long-chain ceramide LCL-30 induces cell death by mitochondrial targeting in SW403 cells. Mol Cancer Ther 5: 1520-1529, 2006.
17. Dahm F, Bielawska A, Nocito A, Georgiev P, Szulc ZM, Bielawski J, Jochum W, Dindo D, Hannun YA and Clavien PA: Mitochondrially targeted ceramide LCL-30 inhibits colorectal cancer in mice. Br J Cancer 98: 98-105, 2008.
18. Bielawska A, Bielawski J, Szulc ZM, Mayroo N, Liu X, Bai A, Elojeimy S, Rembiesa B, Pierce J, Norris JS and Hannun YA: Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorg Med Chem 16: 1032-1045, 2008.
19. Separovic D, Bielawski J, Pierce JS, Merchant S, Tarca AL, Ogretmen B and Korbelik M: Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas. Br J Cancer 100: 626-632, 2009.
20. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z and Kolesnick R: Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82: 405-414, 1995.
21. Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE and Cabot MC: Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemother Pharmacol 47: 444-450, 2001.
22. Perry DK, Carton J, Shah AK, Meredith F, Uhlinger DJ and Hannun YA: Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J Biol Chem 275: 9078-9084, 2000.
23. Senkal CE, Ponnusamy S, Rossi MJ, Bialewski J, Sinha D, Jiang JC, Jazwinski SM, Hannun YA and Ogretmen B: Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas. Mol Cancer Ther 6: 712-722, 2007.
24. Min J, Mesika A, Sivaguru M, Van Veldhoven PP, Alexander H, Futerman AH and Alexander S: (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Mol Cancer Res 5: 801-812, 2007.
25. Wang H, Maurer BJ, Liu YY, Wang E, Allegood JC, Kelly S, Symolon H, Liu Y, Merrill AH Jr, Gouaze-Andersson V, Yu JY, Giuliano AE and Cabot MC: N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Mol Cancer Ther 7: 2967-2976, 2008.
26. Separovic D, Hanada K, Maitah MY, Nagy B, Hang I, Tainsky MA, Kraniak JM and Bielawski J: Sphingomyelin synthase 1 suppresses ceramide production and apoptosis post-photodamage. Biochem Biophys Res Commun 358: 196-202, 2007.
27. Separovic D, Semaan L, Tarca AL, Awad Maitah MY, Hanada K, Bielawski J, Villani M and Luberto C: Suppression of sphingomyelin synthase 1 by small interference RNA is associated with enhanced ceramide production and apoptosis after photodamage. Exp Cell Res 314: 1860-1868, 2008.
28. Wispriyono B, Schmelz E, Pelayo H, Hanada K and Separovic D: A role for the de novo sphingolipids in apoptosis of photo-sensitized cells. Exp Cell Res 279: 153-165, 2002.
29. Dolgachev V, Farooqui MS, Kulaeva OI, Tainsky MA, Nagy B, Hanada K and Separovic D: De novo ceramide accumulation due to inhibition of its conversion to complex sphingolipids in apoptotic photosensitized cells. J Biol Chem 279: 23238-23249, 2004.
30. Dolgachev V, Oberley LW, Huang TT, Kraniak JM, Tainsky MA, Hanada K and Separovic D: A role for manganese superoxide dismutase in apoptosis after photosensitization. Biochem Biophys Res Commun 332: 411-417, 2005.
31. Mitra S and Foster TH: Photophysical parameters, photosensitizer retention and tissue optical properties completely account for the higher photodynamic efficacy of meso-tetra-hydroxyphenylchlorin vs. Photofrin. Photochem Photobiol 81: 849-859, 2005.
32. Hopper C, Niziol C and Sidhu M: The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. Oral Oncol 40: 372-382, 2004.
33. Khurana D, Martin EA, Kasperbauer JL, O'Malley BW Jr, Salomao DR, Chen L and Strome SE: Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head Neck 23: 899-906, 2001.
34. Sun J, Cecic I, Parkins CS and Korbelik M: Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours. Photochem Photobiol Sci 1: 690-695, 2002.
35. Bielawski J, Szulc ZM, Hannun YA and Bielawska A: Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39: 82-91, 2006.
36. Biel MA: Photodynamic therapy treatment of early oral and laryngeal cancers. Photochem Photobiol 83: 1063-1068, 2007.
37. Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL and Madhusudan S: Biomarkers of response to therapy in oesophago-gastric cancer. Gut 58: 127-143, 2009.
38. Senkal CE, Ponnusamy S, Bielawski J, Hannun YA and Ogretmen B: Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J 24: 296-308, 2010.
39. Pyne NJ and Pyne S: Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10: 489-503, 2010.